-
公开(公告)号：US20240245730A1
公开(公告)日：2024-07-25
申请号：US18561849
申请日：2022-05-17
Applicant: Wisconsin Alumni Research Foundation
Inventor： Jacques GALIPEAU , Pradyut PAUL
CPC classification number: A61K35/39 , A61P3/10 , A61P37/06 , C07K14/70532 , C12N5/0676 , C12N9/0069 , C12N15/86 , C07K2319/02 , C07K2319/03 , C12N2510/00 , C12N2740/15043 , C12Y113/11052
Abstract: The present invention provides fusion proteins that induce local immune tolerance. The fusion proteins comprise peptides derived the immunoregulatory proteins programmed death ligand-1 (PD-L1) and indolamine 2,3-dioxygenase (IDO). Also provided are nucleic acid constructs encoding said fusion proteins, cells comprising said nucleic acid constructs, and methods of transplanting said cells into a subject.
-
公开(公告)号：US12012614B2
公开(公告)日：2024-06-18
申请号：US17259462
申请日：2020-05-25
Applicant: QINGDAO RESTORE BIOTECHNOLOGY CO., LTD.
Inventor： Bingqiang Zhang , Mengmeng Chen , Cuicui Li , Erpu Wang , Fubin Wang , Wei Zou , Xueqi Fu , Cuijuan Liu
IPC: C12N5/071
CPC classification number: C12N5/0676 , C12N2501/14 , C12N2501/165 , C12N2501/335 , C12N2501/37 , C12N2501/999
Abstract: The present invention belongs to the field of biomedicine, and relates to an inducer for inducing a mesenchymal stem cell to differentiate into an islet cell. An inducer for inducing a mesenchymal stem cell to differentiate into an islet cell consisted of the following components: GLP-1, parathyroid hormone, paracetamol, rapamycin, icariin, trametinib, EPO and VEGF. Each component in a inducer for inducing a mesenchymal stem cell to differentiate into an islet cell of the present invention is safe and non-toxic, requiring fewer steps and short time to induce differentiation, with high induction efficiency.
-
3.发明公开
公开(公告)号：US20240174983A1
公开(公告)日：2024-05-30
申请号：US18354452
申请日：2023-07-18
Applicant: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
Inventor： Andrew F. STEWART , Courtney ACKEIFI , Peng WANG , Bob DEVITA
IPC: C12N5/071 , A61K31/437 , A61K38/22 , A61P3/10 , A61P5/48
CPC classification number: C12N5/0676 , A61K31/437 , A61K38/22 , A61P3/10 , A61P5/48 , C12N2501/335 , C12N2501/727
Abstract: Disclosed herein are methods of increasing cell proliferation in a population of pancreatic beta cells. Also disclosed are methods of treating a subject for a condition associated with insufficient insulin secretion. Also disclosed is a composition comprising a DYRK1A inhibitor and a GLP1R agonist. The disclosure further describes a method of regenerating pancreatic beta cells in a transplant patient.
-
公开(公告)号：US20240117319A1
公开(公告)日：2024-04-11
申请号：US18391831
申请日：2023-12-21
Applicant: Vertex Pharmaceuticals Incorporated
Inventor： Yeh-Chuin POH , George HARB , Felicia J. PAGLIUCA
CPC classification number: C12N5/0676 , C12N5/0031 , C12N2506/22 , C12N2509/10 , C12N2527/00
Abstract: The present application discloses cell clusters resembling the function and characteristics of endogenous pancreatic islets, and methods for making and using such cell clusters.
-
公开(公告)号：US20240091270A1
公开(公告)日：2024-03-21
申请号：US18033760
申请日：2021-10-26
Inventor： Kedar Ghimire , Natasha Rogers
IPC: A61K35/39 , A61P3/10 , C07K16/28 , C12N5/071 , C12N15/113
CPC classification number: A61K35/39 , A61P3/10 , C07K16/2803 , C12N5/0676 , C12N15/1138 , A61K2039/505
Abstract: The present invention generally relates to modulating insulin expression and production by targeting CD47. In a particular aspect, the invention relates increasing insulin expression by silencing or blocking CD47. In another aspect, the present invention relates to the delivery of insulin to a subject by pancreatic beta islet cells. Specifically, the present invention relates to the production of modified pancreatic beta islet cells that have increased insulin expression and production resulting from silencing or blocking CD47, which are suitable for beta cell transplantation, and methods of their production.
-
公开(公告)号：US11896622B2
公开(公告)日：2024-02-13
申请号：US16679100
申请日：2019-11-08
Applicant: ViaCyte, Inc.
Inventor： Laura Martinson , Evert Kroon , Kevin D'Amour , Emmanuel Edward Baetge
CPC classification number: A61K35/39 , A61K38/26 , A61K38/28 , C12N5/0676 , C12N5/0678 , A61K35/12 , C12N2500/38 , C12N2501/10 , C12N2501/105 , C12N2501/113 , C12N2501/115 , C12N2501/119 , C12N2501/12 , C12N2501/16 , C12N2501/33 , C12N2501/385 , C12N2501/41 , C12N2501/415 , C12N2501/42 , C12N2501/58 , C12N2501/999 , C12N2506/02
Abstract: Disclosed herein are methods of producing pancreatic hormone-expressing cells by first differentiating pluripotent cells in cell culture so as to produce endodermal cells, the endodermal cells being competent to further differentiate into hormone-expressing cells capable of secreting at least one pancreatic hormone in response to a physiological signal, and then, transplanting the cultured endodermal cells into an organism, such as an organism in need of an endocrine cell therapy.
-
公开(公告)号：US20240002807A1
公开(公告)日：2024-01-04
申请号：US18210821
申请日：2023-06-16
Applicant: Janssen Biotech, Inc.
Inventor： Alireza Rezania , Jean Xu
CPC classification number: C12N5/0676 , C12N5/067 , A61K35/39 , C12N2501/115 , C12N2501/16 , C12N2501/385 , C12N2501/727 , C12N2501/70 , C12N2506/02 , C12N2533/90 , C12N2501/119 , C12N2501/42 , C12N2501/415
Abstract: The present invention provides methods to promote the differentiation of pluripotent stem cells. In particular, the present invention provides an improved method for the formation of pancreatic endoderm, pancreatic hormone expressing cells and pancreatic hormone secreting cells. The present invention also provides methods to promote the differentiation of pluripotent stem cells without the use of a feeder cell layer.
-
8.发明授权
公开(公告)号：US11788064B2
公开(公告)日：2023-10-17
申请号：US16959390
申请日：2019-01-05
Applicant: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
Inventor： Andrew F. Stewart , Courtney Ackeifi , Peng Wang , Bob Devita
CPC classification number: C12N5/0676 , A61K31/437 , A61K38/22 , A61P3/10 , A61P5/48 , C12N2501/335 , C12N2501/727
Abstract: Disclosed herein are methods of increasing cell proliferation in a population of pancreatic beta cells. Also disclosed are methods of treating a subject for a condition associated with insufficient insulin secretion. Also disclosed is a composition comprising a DYRK1 A inhibitor and a GLP1R agonist. The disclosure further describes a method of regenerating pancreatic beta cells in a transplant patient.
-
公开(公告)号：US20230293812A1
公开(公告)日：2023-09-21
申请号：US18188304
申请日：2023-03-22
Applicant: ViaCyte, Inc.
Inventor： Chad Green , Laura Martinson , Erik Olson , Val Anthony Bellora , Leah Elliott , Richard Alexander Grant , Donald Koenig , Giacomo Strollo
CPC classification number: A61M5/14276 , A61F2/022 , A61M5/142 , A61M37/0069 , B65B3/003 , A61M2209/045 , C12N5/0676
Abstract: Embodiments herein describe tools, instruments and methods for aseptic loading, dispensing and/or delivering cells into an implantable device and aseptically and selectively sealing a device inside a sterile package as well as and storing and preparing for shipment the cell-filled device.
-
公开(公告)号：US20230256137A1
公开(公告)日：2023-08-17
申请号：US18138904
申请日：2023-04-25
Applicant: ViaCyte, Inc.
Inventor： Laura Martinson , Chad Green , Evert Kroon , Emmanuel Edward Baetge
IPC: A61L27/38 , A61K35/39 , C12N5/071 , A61L27/14 , A61L27/54 , A01N1/02 , A61K38/28 , A61M5/00 , A61F2/02 , A61L27/50 , A61L27/56 , A61M31/00
CPC classification number: A61L27/3804 , A61K35/39 , C12N5/0676 , A61L27/14 , A61L27/54 , A01N1/0221 , A61K38/28 , A61M5/00 , A61F2/022 , A61L27/50 , A61L27/56 , C12N5/0678 , A61M31/002 , A61M31/00 , A61K2035/126
Abstract: The present invention relates to methods for encapsulating pancreatic progenitors in a biocompatible semi-permeable encapsulating device. The present invention also relates to production of human insulin in a mammal in response to glucose stimulation.
